Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.
about
Molecular Targeted Intervention for Pancreatic CancerRise and fall of an anti-MUC1 specific antibodyIdentification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.Colorectal cancer immunotherapy.Vaccine prevention of cancer: can endogenous antigens be targeted?Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinomaLentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.The antigenic repertoire of premalignant and high-risk lesions.MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain.Genetically engineered mucin mouse models for inflammation and cancer.MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.Cancer immunoprevention.MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potentialDownregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells.Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonary disease: A population-based cohort study.Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas.Challenges in the research and development of new human vaccines.Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.MUC1 (CD227): a multi-tasked molecule.Cancer Prevention: Lessons Learned and Future Directions.Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings.Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen.2011: the immune hallmarks of cancer.Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant.Abnormally glycosylated MUC1 establishes a positive feedback circuit of inflammatory cytokines, mediated by NF-κB p65 and EzH2, in colitis-associated cancer.Colorectal cancer prevention: Immune modulation taking the stage.
P2860
Q26798453-556ED31F-8870-4887-B365-5AA75087E1B6Q28743508-7E465B24-43E0-45EC-B503-D22377508AFAQ30541685-ABE5988F-F577-4FA9-9986-669135278C80Q33701465-732D5445-2516-47F0-A9D7-92069F0D5BBDQ33783609-5CD05CC6-090E-4B99-98AD-74AA9C8C9389Q34567000-4D755BBD-10A9-4960-9BC6-2EE59C9A5B1FQ35147489-0179033F-0CE9-4740-B63B-AC07CD104C58Q35251460-731CEA8A-D7F4-49E8-8D9B-2A3F66C3ED48Q35605048-3D2B6698-850C-465C-839F-F9A241C45673Q35904634-296C1BDA-2463-4ED4-A626-AB6E51B044E3Q36508191-092BCF84-9BA0-4E35-80F9-1B288CD2F90BQ36723234-1BF79C00-B2A7-4269-B5F6-12956C30374AQ36821095-543D2589-6C66-44E7-8040-20E631A6BD53Q37193096-B4DEFC76-D507-4E7E-9C23-33BAC37CDF34Q37260742-A61543A1-641B-418A-A841-D2047CA533C4Q37662217-05D7C1F6-0995-4DB9-AA73-63C711AC5045Q37895966-B3718EDC-C7DE-4B4E-B925-2089B12F6675Q38096300-DC0D73BF-064E-47A8-8A7E-A3B562C6B265Q38162151-977C334A-7F0B-498A-87D8-F53F5AB51AF3Q38570769-86856B6C-C3AA-469C-886F-7D1ECC571C62Q38652183-A3B3F173-7255-4621-9B0A-38F704094DAAQ39015961-6EB215DC-B50F-4064-B3B0-7667A7BAB901Q39063057-0EF9E701-41CD-41D9-ACE0-A2C9C9B43002Q39189908-DED624A0-4841-4CED-87B1-960E9276CB8AQ42214130-91354E67-A605-4484-A2C6-3EB654E714D5Q42217850-916C2037-AB70-42BB-B680-7BDBF8D657DFQ44241932-105C39A5-F8A0-4C57-A46D-F17A8A1E9F85Q44745178-5AFC98EC-EF8D-4724-9A73-4FDE12F7A957Q47139763-F83AF01F-9627-44BA-9DB6-2A4C72EE6D94Q49391998-1F5CF34D-C4DD-4455-BF6D-134747A5306F
P2860
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Vaccine against MUC1 antigen e ...... litis-associated colon cancer.
@en
Vaccine against MUC1 antigen e ...... litis-associated colon cancer.
@nl
type
label
Vaccine against MUC1 antigen e ...... litis-associated colon cancer.
@en
Vaccine against MUC1 antigen e ...... litis-associated colon cancer.
@nl
prefLabel
Vaccine against MUC1 antigen e ...... litis-associated colon cancer.
@en
Vaccine against MUC1 antigen e ...... litis-associated colon cancer.
@nl
P2093
P2860
P1476
Vaccine against MUC1 antigen e ...... litis-associated colon cancer.
@en
P2093
Jean Gariépy
Olivera J Finn
Pamela L Beatty
Sarangarajan Ranganathan
Sowmya Narayanan
P2860
P304
P356
10.1158/1940-6207.CAPR-09-0194
P577
2010-03-23T00:00:00Z